CN115916205A - 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 - Google Patents
使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 Download PDFInfo
- Publication number
- CN115916205A CN115916205A CN202180035499.8A CN202180035499A CN115916205A CN 115916205 A CN115916205 A CN 115916205A CN 202180035499 A CN202180035499 A CN 202180035499A CN 115916205 A CN115916205 A CN 115916205A
- Authority
- CN
- China
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- compound
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US63/005,095 | 2020-04-03 | ||
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| US63/051,767 | 2020-07-14 | ||
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115916205A true CN115916205A (zh) | 2023-04-04 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180035499.8A Pending CN115916205A (zh) | 2020-04-03 | 2021-04-01 | 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125906A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520469A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220163986A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916205A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021249129B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019846A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177390A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022002699A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296990A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012310A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907406B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202825A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899163B (zh) * | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
| BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| EP3626239B1 (en) | 2017-05-18 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ezh2 inhibitor combined with btk inhibitor for treating tumor |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| JP2022500408A (ja) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | エンザスタウリンとbtkの阻害剤との組合せおよびその使用 |
| EP3914250A1 (en) | 2019-01-22 | 2021-12-01 | F. Hoffmann-La Roche AG | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
| TWI899163B (zh) | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
-
2021
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 AU AU2021249129A patent/AU2021249129B2/en active Active
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022019846A2 (pt) | 2022-11-22 |
| TW202203925A (zh) | 2022-02-01 |
| IL296990A (en) | 2022-12-01 |
| AU2021249129B2 (en) | 2026-06-04 |
| JP2023520469A (ja) | 2023-05-17 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
| TWI907406B (zh) | 2025-12-11 |
| EP4125906A1 (en) | 2023-02-08 |
| AU2021249129A1 (en) | 2022-10-20 |
| CL2022002699A1 (es) | 2023-03-31 |
| WO2021202825A1 (en) | 2021-10-07 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| MX2022012310A (es) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12605376B2 (en) | Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase | |
| JP5819328B2 (ja) | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 | |
| JP2026082835A (ja) | ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 | |
| US20240287176A1 (en) | Methods of treatment of autoimmune disorders using ilt7 binding proteins | |
| JP2024542148A (ja) | ヒト化抗cd40抗体の医薬組成物およびその使用 | |
| AU2024264495A1 (en) | Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha | |
| CN112437665A (zh) | 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物 | |
| AU2023297461A1 (en) | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis | |
| TW202517276A (zh) | 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法 | |
| WO2025045766A1 (en) | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same | |
| AU2023393624A1 (en) | Anti-ilt7 binding agents for the treatment and prevention of myositis | |
| RU2858695C2 (ru) | Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| RU2858696C2 (ru) | Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| HK40087403A (en) | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton’s tyrosine kinase | |
| HK40082153A (en) | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase | |
| KR20250162587A (ko) | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 | |
| CN117940161A (zh) | 伊奈利珠单抗及其在治疗或预防IgG4相关疾病中的使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40087403 Country of ref document: HK |